The Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality

The US Food and Drug Administration (FDA) authorized treatment of hospitalized COVID-19 patients with Convalescent Plasma (CCP) via the Expanded Access Program (EAP) and the Emergency Use Authorization (EUA), leading to the use of CCP in some 500,000 patients during the first year of the pandemic.

You can check the medical research right here.